Crisaborole Patent Expiration
Crisaborole is Used for managing mild to moderate atopic dermatitis. It was first introduced by Anacor Pharmaceuticals Inc
Crisaborole Patents
Given below is the list of patents protecting Crisaborole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Eucrisa |
US8168614 (Pediatric) | Boron-containing small molecules as anti-inflammatory agents | Jul 20, 2030 | Anacor Pharms Inc |
| Eucrisa | US8168614 | Boron-containing small molecules as anti-inflammatory agents | Jan 20, 2030 | Anacor Pharms Inc |
| Eucrisa |
US8039451 (Pediatric) | Boron-containing small molecules | Dec 29, 2029 | Anacor Pharms Inc |
| Eucrisa | US8039451 | Boron-containing small molecules | Jun 29, 2029 | Anacor Pharms Inc |
| Eucrisa |
US8501712 (Pediatric) | Boron-containing small molecules as anti-inflammatory agents | Aug 16, 2027 | Anacor Pharms Inc |
| Eucrisa |
US9682092 (Pediatric) | Boron-containing small molecules as anti-inflammatory agents | Aug 16, 2027 | Anacor Pharms Inc |
| Eucrisa | US8501712 | Boron-containing small molecules as anti-inflammatory agents | Feb 16, 2027 | Anacor Pharms Inc |
| Eucrisa | US9682092 | Boron-containing small molecules as anti-inflammatory agents | Feb 16, 2027 | Anacor Pharms Inc |
Crisaborole's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List